(Q34131899)

31 July 2017

title

Hypertensive nephropathy: prevention and treatment recommendations (English)

1 reference

31 July 2017

main subject

hypertensive nephropathy

1 reference

Peter D Hart

1

1 reference

31 July 2017

George L Bakris

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

18 August 2010

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

11

1 reference

31 July 2017

issue

16

1 reference

31 July 2017

page(s)

2675-2686

1 reference

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Is proteinuria a plausible target of therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Causes and consequences of increased sympathetic activity in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Mechanisms for the elevation of blood pressure in human renal disease. Preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

"Step" vs. "dynamic" autoregulation: implications for susceptibility to hypertensive injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Interactions between the sympathetic nervous system and the kidneys in arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Pulse pressure, endothelium function, and arterial stiffness in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Hypertension-associated kidney disease: perhaps no more

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Chromogranin A polymorphisms are associated with hypertensive renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Clinical importance of microalbuminuria in diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Microalbuminuria and oxidative stress in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Association between microalbuminuria and the metabolic syndrome: NHANES III

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Time to abandon microalbuminuria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Antihypertensive therapy in the presence of proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

The kidney, hypertension, and remaining challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Does dietary salt increase the risk for progression of kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Thiazide diuretics, potassium, and the development of diabetes: a quantitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Risk factor assessment for new onset diabetes: literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Long-term adaptation of renal ion transporters to chronic diuretic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Differential effects of calcium antagonist subclasses on markers of nephropathy progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Management of hypertensive chronic kidney disease: role of calcium channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Calcium antagonists: effects on cardio-renal risk in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Carvedilol, an Antihypertensive Drug with Antioxidant Properties, Protects against Glycerol-Induced Acute Renal Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485612

10.1517/14656566.2010.485612

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference